Shares of Citius Pharmaceuticals jumped 9% to $0.49 after its majority-owned subsidiary reported that shipments of its skin-cancer treatment to U.S. wholesalers more than doubled last quarter. The headline number is striking for a drug barely ten months on the market — but a closer look at the data raises a question shareholders cannot yet answer: Is the growth driven by patients, or by distributors stocking shelves?
Wholesaler Shipments Soared, but Hospital Orders Barely Budged. The company sold 792 units to wholesalers in the quarter ended September 30, up from 360 the prior quarter — a 120% leap. Yet prescribing centers ordered just 950 vials from those wholesalers, compared to 926 the quarter before — only a 3% increase. That 117-percentage-point gap between sell-in (what goes to distributors) and sell-through (what hospitals actually order) is a classic red flag for channel loading. The company books revenue when wholesaler orders are filled, not when institutions buy , meaning Q4 revenue will reflect the big shipment number, but future quarters could stall if distributor shelves are already full.
More Hospitals Are Signing On, but the Runway Target Looks Steep. Fifty-four institutions have now ordered the drug, up from 44 in mid-August . Management says it is "more than halfway" to getting the treatment on formulary — a hospital's approved drug list — at 100 priority institutions by year-end . Reaching that goal would double the current ordering base in roughly two months, an ambitious pace for a micro-cap with a newly expanded sales force that only reached nationwide coverage in August .
Cash Is Running Out Fast. The company posted a net loss of $37.5 million over six months, held just $4.6 million in cash, and carried negative working capital of roughly $23.3 million . Management has flagged "substantial doubt" about continuing operations beyond November 2026 — next month. Citius's market capitalization sits at approximately $11.7 million , meaning any capital raise would heavily dilute existing holders.
The Market Opportunity Is Real, but Execution Must Accelerate. Management estimates the U.S. market for the drug's target disease exceeds $400 million , and the treatment is the first new FDA-approved systemic therapy for this type of skin lymphoma in over seven years . With near-universal insurance coverage secured , the commercial infrastructure exists. But until institutional orders climb in tandem with wholesaler shipments — and until the balance sheet is stabilized — today's rally is built on promise, not proof.